Back

Lymphatic endothelial cell-targeting lipid nanoparticles delivering VEGFC mRNA improve lymphatic function after injury

Michalaki, E.; Chin, R.; Jeong, K.; Qi, Z.; Liebman, L. N.; Gonzalez-Vargas, Y.; Echeverri, E. S.; Paunovska, K.; Muramatsu, H.; Pardi, N.; Tamburini, B. J.; Jakus, Z.; Dahlman, J. E.; Dixon, J. B.

2024-07-31 bioengineering
10.1101/2024.07.31.605343 bioRxiv
Show abstract

Dysfunction of the lymphatic system following injury, disease, or cancer treatment can lead to lymphedema, a debilitating condition with no cure. Advances in targeted therapy have shown promise for treating diseases where conventional therapies have been ineffective and lymphatic vessels have recently emerged as a new therapeutic target. Lipid nanoparticles (LNPs) have emerged as a promising strategy for tissue specific delivery of nucleic acids. Currently, there are no approaches to target LNPs to lymphatic endothelial cells, although it is well established that intradermal (ID) injection of nanoparticles will drain to lymphatics with remarkable efficiency. To design an LNP that would effectively deliver mRNA to LEC after ID delivery, we screened a library of 150 LNPs loaded with a reporter mRNA, for both self-assembly and delivery in vivo to lymphatic endothelial cells (LECs). We identified and validated several LNP formulations optimized for high LEC uptake when administered ID and compared their efficacy for delivery of functional mRNA with that of free mRNA and mRNA delivered with a commercially available MC3-based LNP (Onpattro). The lead LEC-specific LNP was then loaded with VEGFC mRNA to test the therapeutic advantage of the LEC-specific LNP (namely, LNP7) for treating a mouse tail lymphatic injury model. A single dose of VEGFC mRNA delivered via LNP7 resulted in enhanced LEC proliferation at the site of injury, and an increase in lymphatic function up to 14-days post-surgery. Our results suggest a therapeutic potential of VEGFC mRNA lymphatic-specific targeted delivery in alleviating lymphatic dysfunction observed during lymphatic injury and could provide a promising approach for targeted, transient lymphangiogenic therapy. One Sentence SummaryDevelopment of a novel lymphatic endothelial cell-targeting lipid nanoparticle via in vivo screening for mRNA delivery improves lymphatic regeneration and function after injury.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Bioengineering & Translational Medicine
21 papers in training set
Top 0.1%
17.3%
2
Advanced Therapeutics
15 papers in training set
Top 0.1%
8.3%
3
Journal of Controlled Release
39 papers in training set
Top 0.1%
6.7%
4
Molecular Therapy
71 papers in training set
Top 0.5%
4.8%
5
Scientific Reports
3102 papers in training set
Top 38%
3.6%
6
Journal of Biomedical Materials Research Part A
18 papers in training set
Top 0.1%
3.6%
7
Molecular Pharmaceutics
16 papers in training set
Top 0.1%
3.6%
8
Biomaterials Science
21 papers in training set
Top 0.2%
3.0%
50% of probability mass above
9
Biomaterials
78 papers in training set
Top 0.3%
2.7%
10
Acta Biomaterialia
85 papers in training set
Top 0.3%
2.7%
11
Bioactive Materials
18 papers in training set
Top 0.3%
2.3%
12
Cell Reports Medicine
140 papers in training set
Top 3%
2.1%
13
Nature Communications
4913 papers in training set
Top 49%
1.9%
14
Frontiers in Bioengineering and Biotechnology
88 papers in training set
Top 1%
1.7%
15
Advanced Science
249 papers in training set
Top 11%
1.7%
16
Advanced Functional Materials
41 papers in training set
Top 1%
1.7%
17
ACS Biomaterials Science & Engineering
37 papers in training set
Top 0.6%
1.6%
18
Science Advances
1098 papers in training set
Top 22%
1.3%
19
Advanced Healthcare Materials
71 papers in training set
Top 1%
1.3%
20
Pharmaceutics
21 papers in training set
Top 0.3%
1.2%
21
iScience
1063 papers in training set
Top 23%
1.1%
22
Nano Letters
63 papers in training set
Top 2%
0.9%
23
Biofabrication
32 papers in training set
Top 0.6%
0.9%
24
eLife
5422 papers in training set
Top 52%
0.9%
25
ACS Nano
99 papers in training set
Top 3%
0.9%
26
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 43%
0.8%
27
Cellular and Molecular Bioengineering
21 papers in training set
Top 0.3%
0.7%
28
Small Methods
26 papers in training set
Top 1%
0.7%
29
Cytotherapy
14 papers in training set
Top 0.4%
0.7%
30
ACS Applied Materials & Interfaces
39 papers in training set
Top 1%
0.7%